Premix insulin is widely used, with high proportion of positive insulin autoimmune antibody in patients with type 2 diabetes. The positive insulin autoimmune antibody may affect blood glucose control. We aim to explore the management for the positive insulin autoimmune antibody and blood glucose control in these patients, and investigate the immune cells changes with the change of different glucose lowering drugs.

Inclusion Criteria:

• Patients with type 2 diabetes;
• Treated with premix insulin, two or three injections a day, single drug or combination of oral hypoglycemic drugs;
• The treatment regimen was stable for more than 2 months;
• With positive insulin antibody

Exclusion Criteria:

• Patients treated with GLP-1 agonist in the last 3 months;
• Allergic to insulin;
• Impaired liver and renal function (ALT 2.5 times higher than the upper limit of normal value; serum creatinine was 1.3 times higher than the upper limit of normal);
• A history of drug abuse and alcohol dependence;
• Used systemic glucocorticoids therapy in recent 3 months;
• Patients with infection or stress within four weeks;
• Patients who cannot tolerate FGM;
• Pregnant or preparing to become pregnant;
• Considered unsuitable to participate by the investigator.